Radiological Imaging in Hepatobiliary and Pancreatic Malignancies

  • Suyash KulkarniEmail author
  • Kunal Gala
  • Nitin Shetty
  • Ashwin Polnaya
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


In this abstracts, of hepato-biliary and pancreatic malignancy major common malignancy like Hepatocellular carcinoma (HCC), Cholangiocarcinoma, Carcinoma of Gall Bladder and Pancreatic carcinoma are describe in detail. Liver malignancy are divided into hyper vascular and hypovascular lesions depending on the contrast enhancement. HCC is occurs predominantly in the setting of cirrhosis and is one tumour which is diagnosed on imaging. Others liver and cystic pancreatic malignancy are tabulated and given overview. Cholangiocarcinoma has been classified according to the anatomical origin i.e eitherxintrahepatic or extrahepatic, intrahepatic cholangiocarcinoma are furthur divided into peripheral and hilar. CT and MRI with MRCP are useful in Carcinoma of Gall bladder to know the local extend of the disease. Pancreatic MRI contrast media are described since they are important for contrast enhancement and functional imaging. Resectability criteria for pancreatic malignancy is important for radiologist which needs to be describe in his report.


  1. 1.
    Nino-Murcia M, Olcott EW, Jeffrey RB Jr, et al. Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology. 2000;215:746–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Danet IM, Semelka RC, Leonardou P, et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol. 2003;181:809–17.CrossRefPubMedGoogle Scholar
  3. 3.
    Quillin SP, Atilla S, Brown JJ, et al. Characterization of focal hepatic masses by dynamic contrast enhanced MR imaging: findings in 311 lesions. Magn Reson Imaging. 1997;15:275–85.CrossRefPubMedGoogle Scholar
  4. 4.
    Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145–59.CrossRefPubMedGoogle Scholar
  5. 5.
    Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008;195:829–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Bruix J. Sherman M; Practice Guidelines Committee American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRefPubMedGoogle Scholar
  7. 7.
    Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and Future Directions. Hepatology. 2015;61:1056–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Bruix J, Sherman M, Llovet JM, et al. European Association for the Study of the liver. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Tanaka S, Kitamura T, Imaoka S, et al. Hepatocellular carcinoma: Sonographic and histologic correlation. AJR Am J Roentgenol. 1983;140:701–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Tanaka S, Kitamura T, Fujita M, et al. Colour Doppler flow imaging of liver tumours. AJR Am J Roentgenol. 1990;154:509–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee JH, Lee JM, Kim SJ, et al. Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. Br J Radiol. 2012;85:e573–83.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Okuda K, Musha H, Yamasaki T, et al. Angiographic demonstration of hepatocellular intra hepatic arterio-portal anastomoses in hepatocellular carcinoma. Radiology. 1977;122:53–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Becker-Weidman DJ, Kalb B, Sharma P, et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. Radiology. 2011;261:824–33.CrossRefPubMedGoogle Scholar
  14. 14.
    DJ B, Johnson CD, Stephens DH, et al. Imaging of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. 1988;151:295–9.CrossRefGoogle Scholar
  15. 15.
    McLarney JK, Rucker PT, Bender GN, et al. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. 1999;19:453–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Purysko AS, Remer EM, Coppa CP, Leão Filho HM, Thupili CR, Veniero JC. LI-RADS: A case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics. 2012;32:1977–95. American College of Radiology. Quality and safety resources: Liver Imaging–Reporting and Data System. Available at: Accessed April 22, 2012CrossRefPubMedGoogle Scholar
  17. 17.
    Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    European Association For The Study Of The Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRefGoogle Scholar
  19. 19.
    Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology. 2001;218:27–38.CrossRefPubMedGoogle Scholar
  22. 22.
    Mitchell DG. Liver I Currently available gadolinium chelates. Magn Reson Imaging Clin N Am. 1996;4:37–51.PubMedGoogle Scholar
  23. 23.
    Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging: interrelations between pharmacokinetics and imaging. Investig Radiol. 1993;28:753–61.CrossRefGoogle Scholar
  24. 24.
    Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol. 1990;155:943–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology. 2006;238:531–41.CrossRefPubMedGoogle Scholar
  26. 26.
    Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004;14:559–78.CrossRefPubMedGoogle Scholar
  27. 27.
    Han JK, Choi BI, Kim AY, An SK, Lee JW, Kim TK, et al. Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings. Radiographics. 2002;22:173–87.CrossRefPubMedGoogle Scholar
  28. 28.
    Valls C, Guma A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25:490–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Fan ZM, Yamashita Y, Harada M, et al. Intrahepatic cholangiocarcinoma, spin-echo and contrast enhanced dynamic MR imaging. AJR Am J Roentgenol. 1993;161:313–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512–22.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11:671–81.CrossRefPubMedGoogle Scholar
  32. 32.
    Levy AD, Murakata LA, Rohrmann CA. Gallbladder carcinoma: radiologic–pathologic correlation. Radiographics. 2001;21:295–314.CrossRefPubMedGoogle Scholar
  33. 33.
    Franquet T, Montes M, Ruiz de Azua Y, Jimenez FJ, Cozcolluela R. Primary gallbladder carcinoma: imaging findings in 50 patients with pathologic correlation. Gastrointest Radiol. 1991;16:143–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Ros PR, Mortele KJ. Imaging features of pancreatic neoplasms. JBR-BTR. 2001;84(6):239–49.PubMedGoogle Scholar
  35. 35.
    Inokuma T, Okamoto T, Ogami T, et al. Diagnosis of pancreatic cancer with FDG-PET: comparison with CT, US and endoscopic US. Gut. 1996;39(suppl 3):12.Google Scholar
  36. 36.
    Tempero M, Arnoletti JP, Behrman S, et al. Clinical Practice Guidelines in Oncology: pancreatic adenocarcinoma. National Comprehensive Cancer. Network. 2010; version 2. Available at Accessed July 2010.
  37. 37.
    Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19(2):195–211.CrossRefPubMedGoogle Scholar
  38. 38.
    Sarr MG, Kendrick ML, Nagorney DM, Thompson GB, Farley DR, Farnell MB. Cystic neoplasms of the pancreas: benign to malignant epithelial neoplasms. Surg Clin North Am. 2001;81(3):497–509.CrossRefPubMedGoogle Scholar
  39. 39.
    Sarr MG, Carpenter HA, Prabhakar LP, et al. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg. 2000;231(2):205–12.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Manfredi R, Graziani R, Motton M, et al. Main pancreatic duct intraductal papillary mucinous neoplasms: accuracy of MR imaging in differentiation between benign and malignant tumors compared with histopathologic analysis. Radiology. 2009;253(1):106–15.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Suyash Kulkarni
    • 1
    Email author
  • Kunal Gala
    • 1
  • Nitin Shetty
    • 1
  • Ashwin Polnaya
    • 1
  1. 1.Department of RadiologyTata Memorial CentreMumbaiIndia

Personalised recommendations